Salles, Gilles, Schuster, Stephen J., Fischer, Luca, Kuruvilla, John, Patten, Piers Em, von Tresckow, Bastian, Smith, Sonali M., Ubieto, Ana Isabel Jiminez, Davis, Keith L., Nagar, Saurabh P. ORCID: 0000-0003-4616-0926, Zhang, Jie, Bollu, Vamsi, Jousseaume, Etienne, Ramos, Roberto, Wang, Yucai and Link, Brian K. (2022). A Retrospective Cohort Study of Treatment Outcomes of Adult Patients With Relapsed or Refractory Follicular Lymphoma (ReCORD-FL). Hemasphere, 6 (7). PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. ISSN 2572-9241

Full text not available from this repository.

Abstract

This study (ReCORD-FL) sought to construct a historical control cohort to augment single-arm trials in relapsed/refractory follicular lymphoma (r/r FL). A retrospective study in 10 centers across North America and Europe was conducted. Adults with grade 1-3A FL were required to be r/r after >= 2 therapy lines including an anti-CD20 and an alkylator. After first becoming r/r, patients were required to initiate >= 1 additional therapy line, which defined the study index date. Endpoints were observed from start of each therapy line (including index line) until death, last follow-up, or December 31, 2020. Endpoints were complete response (CR) rate, overall response rate (ORR), time to next treatment or death (TNT-D), event-free survival (EFS), and overall survival (OS). One hundred eighty-seven patients were identified. Most patients' (80.2%) index therapy occurred in third line (3L) (range, 3L-6L). Median follow-up from FL diagnosis was 9 years (range, 1-21 years). CR and ORR to the index therapy were 39.0% and 70.6%, respectively. Median (95% confidence interval) EFS from index was 14.6 (11.0-18.0) months; median OS from index was 10.6 years. Outcomes worsened across successive treatment lines and for patients who were double refractory (r/r to both an anti-CD20 monoclonal antibody and an alkylator) or POD24 (progressed <= 24 months after front-line anti-CD20) at index. Findings demonstrate the unmet need of FL patients with multiply relapsed, double refractory, or POD24 disease. Based on robustness of the historical data collected and comparability with a previous study (SCHOLAR-5), ReCORD-FL presents a valuable source of control data for comparative studies in r/r FL.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Salles, GillesUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Schuster, Stephen J.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Fischer, LucaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kuruvilla, JohnUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Patten, Piers EmUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
von Tresckow, BastianUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Smith, Sonali M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Ubieto, Ana Isabel JiminezUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Davis, Keith L.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Nagar, Saurabh P.UNSPECIFIEDorcid.org/0000-0003-4616-0926UNSPECIFIED
Zhang, JieUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Bollu, VamsiUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Jousseaume, EtienneUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Ramos, RobertoUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Wang, YucaiUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Link, Brian K.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-695656
DOI: 10.1097/HS9.0000000000000745
Journal or Publication Title: Hemasphere
Volume: 6
Number: 7
Date: 2022
Publisher: LIPPINCOTT WILLIAMS & WILKINS
Place of Publication: PHILADELPHIA
ISSN: 2572-9241
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
R-CVP; RITUXIMAB; CYCLOPHOSPHAMIDE; VINCRISTINE; PREDNISONE; CHOP; DOXORUBICIN; THERAPYMultiple languages
HematologyMultiple languages
URI: http://kups.ub.uni-koeln.de/id/eprint/69565

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item